Othmer S C, Othmer E, Preskorn S H, Mac D
Department of Psychiatry, University of Kansas Medical Center, Kansas City 66103.
J Clin Psychiatry. 1988 Aug;49(8):310-2.
In a prospective, controlled, double-blind study, 37 patients with major depressive disorder were subclassified into primary depression (N = 25) and secondary (N = 12) depression and treated with either amitriptyline (primary depressives N = 13, secondary depressives N = 6) or bupropion (primary depressives N = 12, secondary depressives N = 6). A differential response to the novel antidepressant bupropion was observed between the two diagnostic subgroups, but no differential response to amitriptyline was observed; patients with primary depression and secondary depression responded equally well to amitriptyline but not to bupropion. Our results provide pharmacological evidence supporting the usefulness of this subclassification of depression.
在一项前瞻性、对照、双盲研究中,37例重度抑郁症患者被分为原发性抑郁症(N = 25)和继发性抑郁症(N = 12)两组,并分别接受阿米替林治疗(原发性抑郁症患者N = 13,继发性抑郁症患者N = 6)或安非他酮治疗(原发性抑郁症患者N = 12,继发性抑郁症患者N = 6)。两个诊断亚组对新型抗抑郁药安非他酮的反应存在差异,但对阿米替林的反应无差异;原发性抑郁症和继发性抑郁症患者对阿米替林的反应同样良好,但对安非他酮的反应不同。我们的结果提供了药理学证据,支持这种抑郁症分类的实用性。